The Arithmetic of Dying
In 2004, a Cincinnati conglomerate with roots in pest control and plumbing services made a $1.1 billion bet that the most predictable thing about American healthcare was death. Chemed Corporation — then a holding company whose largest asset was Roto-Rooter, the nation's dominant drain-cleaning franchise — acquired VITAS Healthcare Corporation, the largest for-profit hospice provider in the United States, and in doing so yoked together two businesses that share almost nothing in common except an orientation toward the inevitable. Pipes will clog. People will die. The strategic insight was not morbid; it was actuarial.
Two decades later, that bet has compounded into something remarkable. Chemed trades at a market capitalization exceeding $9 billion, has generated total shareholder returns that dwarf the S&P 500, and operates a business model so durable that its two segments — one caring for the terminally ill, the other unclogging America's sewers — have produced combined operating margins above 15% through recessions, pandemics, and regulatory upheaval. The marriage of hospice care and home services is not a strategy that any business school case would recommend. It is a strategy that works precisely because both businesses share a deeper structural logic: recurring, non-discretionary demand driven by demographic certainty, delivered through local labor networks that resist digital disruption. The algorithmic economy cannot send a robot to comfort a dying grandmother. It cannot send one to snake a drain, either.
The story of Chemed is, at its core, a story about capital allocation in industries that Wall Street would rather not think about — and about a family-influenced management team that has spent decades exploiting that cognitive arbitrage.
By the Numbers
Chemed Corporation — 2024 Snapshot
$2.43BTotal revenue (FY2024)
~$9.2BMarket capitalization (mid-2025)
~16,000Employees across both segments
$1.75BVITAS segment revenue (FY2024)
$678MRoto-Rooter segment revenue (FY2024)
~200,000Patients admitted to VITAS hospice annually
60+Years since Roto-Rooter's founding
~18%Share of U.S. for-profit hospice market (VITAS)
A Conglomerate Born of Chemicals and Conviction
Chemed's origins have almost nothing to do with its present form. The company was founded in 1970 as a subsidiary of W.R. Grace & Co., the diversified chemical conglomerate, spun off to house a collection of healthcare and service businesses that didn't fit the parent's industrial portfolio. The name itself — "Chem-ed" — nods to its chemical lineage. For its first three decades, Chemed was a classic holding company: a little bit of everything, a lot of nothing. It owned pieces of patient care companies, dabbled in staffing services, and accumulated a reputation for competent but unspectacular stewardship.
The transformation began with Kevin McNamara. A lawyer by training who joined Chemed in 1986, McNamara became CEO in 2001 and inherited a company that was, by his own assessment, too diversified to matter. His strategic clarity was blunt: shed everything that wasn't a market leader in a non-discretionary service category. Between 2001 and 2004, McNamara divested peripheral holdings and used the proceeds — plus substantial debt — to acquire VITAS Healthcare for approximately $406 million in cash and assumed obligations that brought the total enterprise value near $1.1 billion. It was a leveraged bet on demographics.
McNamara understood something that the broader market was slow to internalize: the Medicare hospice benefit, established in 1982, had created a government-guaranteed revenue stream tied to the most predictable demographic event in American life. The over-65 population was growing at 3% annually and accelerating. Every one of those people would eventually die, and an increasing percentage of them would choose — or be guided toward — hospice care rather than aggressive end-of-life treatment. The question was not whether hospice would grow, but how fast.
The VITAS Machine
VITAS Healthcare was itself a company with a complicated past. Founded in 1978 by Hugh Westbrook, a former hospital chaplain, and Esther Colliflower, a registered nurse, in Miami-Dade County, Florida, VITAS was among the earliest organizations to operationalize the hospice concept in the United States. The name comes from the Latin word for "lives" — a small irony given that the business exists to serve the dying.
Westbrook and Colliflower built VITAS on a philosophy that was genuinely radical for American healthcare at the time: that dying patients deserved comfort-focused care in their own homes, not futile interventions in hospital ICUs. The model was simple — interdisciplinary teams of nurses, social workers, chaplains, and home health aides providing palliative care, pain management, and family support, primarily in the patient's residence. The payer was almost exclusively Medicare, through the Medicare Hospice Benefit, which reimburses providers on a per-diem basis according to the patient's level of care. This created a business model with unusual characteristics: predictable revenue per patient per day, but a variable — and deeply uncertain — length of stay that determined total revenue per admission.
By the time Chemed acquired it, VITAS was operating in 15 states and the District of Columbia, admitting over 70,000 patients annually, and generating roughly $700 million in revenue. It was already the largest hospice provider in the country by a wide margin, but its growth had been constrained by the capital structure and management distractions of previous corporate ownership (VITAS had been public, then taken private by Chemed's predecessor interest).
Under Chemed, VITAS entered a period of aggressive organic expansion. The playbook was straightforward: hire more sales representatives to build referral relationships with hospitals, physicians, and nursing homes; open new programs in high-growth metropolitan areas where the elderly population was surging; and invest in clinical quality metrics that would differentiate VITAS in a market where many smaller competitors offered inconsistent care. Between 2004 and 2024, VITAS grew revenue from approximately $700 million to $1.75 billion. Average daily census — the critical operating metric in hospice, representing the average number of patients receiving care on any given day — grew from roughly 12,000 to over 20,000.
Our competitive advantage in hospice is not any single thing. It's the combination of clinical depth, geographic density, and referral source relationships that have been built over decades. You can't replicate that with a checkbook.
The economics of hospice care, when executed well, are quietly extraordinary. Medicare reimburses hospice providers at daily rates that vary by level of care — routine home care (the vast majority of patient days) at approximately $210–$215 per day, continuous home care at significantly higher rates, inpatient respite care, and general inpatient care. The key cost is labor: nurses, aides, social workers, chaplains, and physicians who visit patients in their homes. Because the reimbursement is per diem, the provider's margin depends on managing staffing levels against patient census, controlling drug and medical supply costs, and — most critically — managing the length of stay.
This last variable is where hospice economics become ethically fraught and financially fascinating. Medicare's hospice benefit was designed for patients with a prognosis of six months or less to live. In practice, prognostication is imprecise, and lengths of stay vary enormously. A patient admitted with end-stage cancer may live two weeks. A patient admitted with dementia may live two years. For the provider, longer stays generally produce higher total revenue per admission but lower daily margins — because Medicare applies a cap on aggregate per-beneficiary payments, and because the proportion of high-cost clinical events (drug changes, acute symptom management) front-loads in the first weeks of care.
VITAS has historically operated with an average length of stay in the range of 90–100 days and a median length of stay significantly shorter — around 17–21 days — reflecting the reality that a small number of long-stay patients pull the average upward. Managing this distribution is the central art of hospice operations.
Roto-Rooter: The Other Cash Machine
If VITAS represents Chemed's bet on the demographics of dying, Roto-Rooter represents something even more elemental: the physics of plumbing. Founded in 1935 by Samuel Blanc, an Iowa entrepreneur who invented the first electric sewer-cleaning machine, Roto-Rooter became an iconic American brand through relentless franchising and a jingle that embedded itself in the national subconscious. ("Call Roto-Rooter, that's the name, and away go troubles down the drain.")
Chemed acquired Roto-Rooter in 1980, when the service company was already the largest plumbing and drain-cleaning operation in North America. Over the subsequent four decades, Chemed's strategy was methodical and unglamorous: buy back franchises to convert them to company-owned operations, invest in routing technology and dispatch systems, expand service offerings beyond drain cleaning into broader plumbing, HVAC, and water restoration services, and relentlessly build brand awareness through advertising.
The numbers tell the story of compounding in a mature market. Roto-Rooter generates approximately $678 million in annual revenue — roughly 28% of Chemed's total — with operating margins consistently in the 17–20% range. The business has grown revenue at a mid-single-digit compound annual growth rate for over a decade, driven by price increases, service line expansion, and incremental market share gains in a fragmented industry where the next-largest competitors are local operators with a fraction of Roto-Rooter's brand recognition.
What makes Roto-Rooter strategically elegant within the Chemed portfolio is its countercyclicality relative to VITAS and its cash flow profile. Plumbing emergencies are genuinely non-discretionary — a burst pipe at 2 a.m. is not something a homeowner postpones — and demand is modestly correlated with housing age (older homes mean more plumbing failures) rather than economic cycles. The business requires minimal capital expenditure beyond trucks and equipment, generates substantial free cash flow, and provides Chemed with a diversified earnings base that smooths the regulatory and reimbursement volatility inherent in healthcare.
Roto-Rooter provides plumbing, drain cleaning, water restoration, and other related services to both residential and commercial customers. Approximately 90% of Roto-Rooter's revenues come from company-operated locations.
The franchise-to-company-owned conversion strategy deserves particular attention. When Chemed acquired Roto-Rooter, the business was heavily franchised — the classic American franchise model where independent operators paid royalties for the brand and system. Over decades, Chemed systematically repurchased franchise territories, particularly in high-density metropolitan areas where company-owned operations could achieve superior unit economics through centralized dispatch, cross-selling, and brand-consistent service delivery. Today, roughly 90% of Roto-Rooter's revenue comes from company-operated locations. This conversion increased capital intensity modestly but improved margins, customer satisfaction, and strategic control dramatically.
The Capital Allocator's Logic
The deeper question about Chemed is not whether its individual businesses are good — they manifestly are — but why they belong together. The bull case for the conglomerate structure is essentially a capital allocation argument, and it is persuasive.
Both VITAS and Roto-Rooter generate significant free cash flow with modest reinvestment requirements. VITAS's capital expenditures are primarily IT systems, vehicles, and leasehold improvements for inpatient units — perhaps 2–3% of revenue. Roto-Rooter's are trucks, equipment, and technology — similarly modest. Combined, Chemed generates $350–$400 million in annual free cash flow against a revenue base of $2.4 billion, a free cash flow margin in the 15% range that would be the envy of many technology companies.
This cash flow has funded three things: acquisitions (principally the VITAS deal and smaller tuck-in acquisitions in both segments), share repurchases (Chemed has retired over 30% of its shares outstanding in the past decade), and a modest but growing dividend. The share repurchase program, in particular, has been a significant driver of per-share value creation — management has consistently bought back stock at prices that, in hindsight, represented substantial discounts to intrinsic value.
The holding company structure also provides tax efficiency, debt capacity (Chemed can lever the combined entity more cheaply than either business could independently), and — perhaps most importantly — management bandwidth. Chemed's corporate team in Cincinnati is lean: a CEO, CFO, general counsel, and a small corporate staff overseeing two operating subsidiaries that each have their own management teams, operational infrastructure, and performance cultures. The corporate parent's role is capital allocation, incentive design, and strategic oversight — not operational management.
📊
Capital Allocation Track Record
Chemed's deployment of free cash flow, 2015–2024
| Use of Capital | Cumulative (est.) | % of Total FCF |
|---|
| Share Repurchases | ~$2.5B | ~65% |
| Dividends | ~$350M | ~9% |
| Acquisitions/Tuck-ins | ~$300M | ~8% |
| Debt Reduction/Cash Accumulation | ~$700M | ~18% |
The Demographic Tailwind That Cannot Be Legislated Away
Every investment thesis about Chemed begins and ends with a number: 10,000. That is roughly how many Americans turn 65 every day, a pace that began accelerating in 2011 when the oldest Baby Boomers hit retirement age and will not crest until the mid-2030s. The U.S. Census Bureau projects the over-65 population will grow from approximately 58 million in 2023 to 82 million by 2040 — a 41% increase that represents the most certain demand driver in American healthcare.
For VITAS, the math is direct. Approximately 1.7 million Americans die in hospice each year, up from roughly 1.0 million in 2010. Hospice penetration — the percentage of Medicare decedents who use hospice — has risen from about 25% in 2000 to over 50% today. This is not merely a function of aging; it reflects a genuine cultural shift in American attitudes toward end-of-life care, driven by increasing awareness that aggressive interventions in the final months of life often cause suffering without extending meaningful survival. The medical establishment, patients, and families are all moving — slowly, unevenly, but directionally — toward accepting palliative approaches.
For Roto-Rooter, the demographic tailwind is subtler but real. The median age of the U.S. housing stock is approximately 40 years, and aging homes require more plumbing maintenance. Household formation continues at a pace that adds demand. And the "age in place" movement — elderly Americans choosing to remain in their homes rather than move to assisted living — creates a population that needs more home maintenance services, not fewer.
The critical insight is that neither of these demand drivers can be legislated away. Congress can change Medicare reimbursement rates (and frequently does). It cannot change the number of Americans who will turn 85 in 2032.
Navigating the Regulatory Minefield
If demographics are VITAS's tailwind, regulation is its headwind — persistent, unpredictable, and occasionally violent. The Medicare hospice benefit is entirely a creature of federal law, and its economics are dictated by the Centers for Medicare & Medicaid Services (CMS) through an annual rulemaking process that sets reimbursement rates, defines eligibility criteria, and establishes quality standards.
Chemed has navigated this minefield with a mixture of political sophistication and operational discipline, but not without scars. In 2013, the Department of Justice opened an investigation into VITAS's billing practices in its home markets, alleging that the company had admitted patients who were not terminally ill and had provided unnecessarily high levels of care to inflate reimbursements. The investigation — which centered on VITAS's operations in Southern California, Texas, and Florida — hung over the company for years, casting a shadow over the stock and forcing management into an uncomfortable defensive posture.
The investigation eventually led to a $75 million settlement in 2017, paid without admission of wrongdoing — the standard government resolution that satisfies neither prosecutors nor defendants but avoids the existential risk of a trial. Chemed also agreed to a Corporate Integrity Agreement (CIA) with the Office of Inspector General, requiring enhanced compliance monitoring for five years. The experience was chastening. Management overhauled VITAS's admissions processes, invested in compliance infrastructure, and adopted a more conservative approach to patient eligibility that, at the margin, may have slowed admissions growth in the years that followed.
The broader regulatory landscape remains complex. CMS has, in recent years, introduced a new payment model — the Patient-Driven Groupings Model (PDGM) and, more relevant to hospice, the proposed Hospice Special Focus Program — designed to identify and sanction poor-performing hospice providers. A new value-based insurance design (VBID) model for hospice, tested as a CMS Innovation Center demonstration, would allow Medicare Advantage plans to offer hospice benefits, potentially disrupting the traditional fee-for-service hospice model that VITAS was built on. The annual rate update cycle introduces its own uncertainty: for fiscal year 2025, CMS implemented a net hospice payment increase of approximately 2.6%, roughly in line with inflation — a modest positive, but one that barely covers the labor cost inflation pressuring the industry.
This rule updates the hospice payment rates for FY 2025 and includes provisions to strengthen the survey and enforcement process for hospice providers.
For VITAS, the competitive implication of tightening regulation is, paradoxically, positive at the margin. Smaller hospice operators — the industry includes over 5,500 providers, the vast majority with fewer than 100 patients — lack the compliance infrastructure, clinical quality systems, and financial reserves to absorb regulatory shocks. Every new compliance requirement raises the cost of doing business for small operators while barely registering for VITAS. The DOJ investigation, painful as it was, ultimately demonstrated that a $1.75 billion hospice operation could absorb a $75 million settlement, implement a CIA, and continue growing. Most competitors cannot.
The COVID Crucible
The pandemic was, for Chemed, a natural experiment in the resilience of non-discretionary demand — and the results were instructive. COVID-19 hit both segments hard in different ways and at different times, but neither broke.
VITAS experienced a surge in patient mortality in 2020 — hospice patients, overwhelmingly elderly and medically fragile, were disproportionately vulnerable to the virus. Average daily census initially declined as referral patterns were disrupted (hospitals were overwhelmed, physicians were less likely to initiate hospice referrals, and families were reluctant to admit strangers into their homes). But the decline was shallower and shorter than feared. By mid-2021, admissions had recovered and were growing again, driven in part by pent-up demand and in part by the pandemic's broader acceleration of home-based care acceptance.
Roto-Rooter, meanwhile, experienced the opposite dynamic. With Americans spending dramatically more time at home, residential plumbing usage spiked. Service calls increased. The shift to remote work, which persisted well after lockdowns eased, structurally increased demand for residential plumbing services. Roto-Rooter's revenue, which had been growing at 3–5% annually, accelerated to 7–8% in 2021 and 2022.
The combined effect on Chemed was striking: total revenue grew through the pandemic, free cash flow expanded, and the stock — after a brief COVID-driven sell-off — more than doubled from its March 2020 lows to new all-time highs. The pandemic validated the thesis. These businesses are, in the most literal sense, essential.
The Leadership Succession
Kevin McNamara, the architect of the VITAS acquisition and the driving force behind Chemed's transformation, served as CEO from 2001 until his retirement. The transition to his successor — David Williams, who had served as CFO and was elevated to President and CEO — was notable for its smoothness. Williams, a CPA by training who had been with Chemed since 1997, represented continuity rather than disruption. He inherited a capital allocation framework, an operating philosophy, and a dual-segment structure that he had helped build and saw no reason to dismantle.
Under Williams, the strategic emphasis has been on operational optimization rather than transformational M&A. VITAS has invested heavily in technology — clinical documentation systems, predictive analytics for patient acuity, and telehealth capabilities that proved invaluable during COVID — while continuing to grow organically through geographic expansion and referral source development. Roto-Rooter has leaned into digital marketing and online booking platforms, recognizing that the customer acquisition funnel for plumbing services has shifted decisively from the Yellow Pages to Google search results.
The management team is notably stable, modestly compensated relative to healthcare peers, and aligned with shareholders through meaningful equity ownership. Insiders collectively own a significant stake, and the compensation structure ties bonuses to earnings-per-share growth and return on equity — metrics that reward capital efficiency rather than empire-building.
The Hospice Industry's Structural Consolidation
VITAS operates in an industry that is simultaneously growing rapidly and consolidating relentlessly. The U.S. hospice market generates approximately $24–$26 billion in annual revenue, nearly all of it paid by Medicare. The industry includes over 5,500 certified providers, but the distribution is wildly skewed: the top 10 providers account for perhaps 25–30% of the market, and the remaining 5,400+ providers are small, often community-based, and frequently nonprofit.
The consolidation logic is powerful. Medicare's hospice reimbursement is the same regardless of provider size, but the cost of compliance, technology, labor recruitment, and quality management scales dramatically with size. A hospice with 50 patients must meet the same regulatory requirements as one with 5,000 patients. The fixed costs of compliance — a medical director, a quality assurance program, an electronic health records system, an admissions team — are spread over a much smaller revenue base. The result is structural margin compression for small operators and a relentless competitive advantage for scale players.
VITAS has been the primary consolidator. Through a combination of organic expansion (opening new programs in underserved markets) and selective acquisitions (purchasing smaller hospice operators in target geographies), VITAS has grown its market share steadily. The company now operates in approximately 14 states and the District of Columbia, with the heaviest concentration in Florida, Texas, California, and Ohio — states with large and growing elderly populations.
But VITAS is not alone. Amedisys (acquired by UnitedHealth Group's Optum in 2024 for approximately $3.3 billion) and Kindred/Gentiva (owned by Humana through its Kindred at Home subsidiary before various restructurings) represent large-scale hospice competitors backed by even deeper pockets. The entry of managed care organizations — UnitedHealth, Humana, CVS/Aetna — into hospice ownership represents a structural shift in the competitive landscape. These acquirers are not buying hospice for the margins; they're buying it for the ability to control end-of-life spending, which represents a disproportionate share of total healthcare costs.
🏥
U.S. Hospice Industry Landscape
Market structure and key players
| Provider | Estimated Revenue | Market Share | Ownership |
|---|
| VITAS (Chemed) | ~$1.75B | ~7% | Public |
| Amedisys (Optum/UHG) | ~$1.1B hospice | ~4% | UnitedHealth Group |
| Kindred Hospice (Humana) | ~$800M | ~3% | Humana |
| AccordantHealth/Others | Varies | <2% each | Various |
| ~5,400+ Small Providers |
The competitive dynamic is shifting. VITAS's historical advantage — scale, brand, referral relationships, clinical depth — remains formidable. But the entry of health insurers into hospice ownership introduces a new competitive vector: the ability to steer patients toward affiliated hospice providers through Medicare Advantage plans. If the VBID model expands and Medicare Advantage plans begin offering hospice as a covered benefit (currently, hospice is carved out of Medicare Advantage and paid through traditional fee-for-service Medicare), vertically integrated payer-providers like Optum could gain a structural referral advantage that pure-play hospice companies cannot match.
The Peculiar Elegance of the Dual-Segment Model
There is something genuinely strange about a company that derives 72% of its revenue from caring for the dying and 28% from fixing toilets. Analysts have periodically suggested that Chemed should split itself — unlock the "sum of the parts" value by separating VITAS and Roto-Rooter into independent public companies. The argument is superficially compelling: the two businesses have different investor bases, different growth profiles, different risk factors, and different valuation methodologies. A healthcare investor analyzing VITAS must also underwrite Roto-Rooter, and vice versa. The conglomerate discount, the argument goes, suppresses the multiple.
Management has consistently resisted this logic, and the resistance is itself instructive. The argument for keeping the businesses together is not strategic synergy — there are no cross-selling opportunities between hospice patients and plumbing customers, no shared technology platforms, no operational overlap. The argument is financial engineering: two uncorrelated cash flow streams, combined under a single balance sheet, produce a higher-quality earnings stream with lower volatility, better debt capacity, greater capital allocation flexibility, and reduced tax friction on internal capital transfers. The holding company can direct Roto-Rooter's free cash flow toward VITAS growth investments (or vice versa) without the tax and transaction costs that would attend external capital raises by independent entities.
The empirical evidence supports management's position. Chemed's stock has compounded at approximately 14–15% annually over the past two decades, a rate that suggests the market has not, in fact, applied a meaningful conglomerate discount — or, if it has, the discount has been more than offset by the capital allocation advantages of the combined structure.
The Mortality Trade
Step back far enough, and Chemed looks less like a conglomerate and more like a leveraged bet on two of the most certain features of American life: people will age, and infrastructure will decay. The company has no exposure to consumer discretionary spending, no dependence on technological innovation cycles, no meaningful international risk, and no customer concentration. Its largest customer is the U.S. federal government (through Medicare), which is also the most creditworthy payer in the world. Its second-largest customer base is American homeowners, who will always need plumbing.
The risks are real — Medicare reimbursement cuts, labor shortages in healthcare, regulatory enforcement actions, the entry of deep-pocketed vertical integrators into hospice — but they are, critically, risks to the rate of compounding, not to the existence of the business. No plausible regulatory scenario eliminates the Medicare hospice benefit. No plausible competitive scenario drives VITAS's revenue to zero. No plausible technology scenario automates plumbing.
What Chemed has built, over five decades of unglamorous transactions — acquiring Roto-Rooter in 1980, buying VITAS in 2004, repurchasing franchises, retiring shares, settling with the DOJ, surviving the pandemic, and reinvesting the proceeds — is a machine that converts the certainty of human mortality and the certainty of physical decay into a stream of free cash flow that management returns to shareholders with uncommon discipline.
1970Chemed incorporated as a spinoff from W.R. Grace & Co.
1980Acquires Roto-Rooter for approximately $160 million.
2001Kevin McNamara becomes CEO; begins strategic simplification.
2004Acquires VITAS Healthcare for ~$1.1 billion enterprise value.
2013DOJ opens investigation into VITAS billing practices.
2017Settles DOJ investigation for $75 million.
2020Both segments prove resilient through COVID-19.
2024VITAS revenue exceeds $1.75B; total Chemed revenue reaches $2.43B.
In the lobby of Chemed's headquarters on Chemed Center Drive in Cincinnati, there is no grand mission statement about transforming healthcare or disrupting home services. The building is functional. The parking lot is unremarkable. Somewhere inside, a management team is probably reviewing the latest average daily census report from VITAS and the latest service call volume from Roto-Rooter — two numbers, from two businesses that share nothing except the conviction that demand for what they do will exist as long as humans do. The stock ticker scrolls. The pipes keep breaking. The patients keep arriving.
